Prognostic value of pretreatment immune inflammation indices in patients with immune-related tumors

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shigdar S, Li Y, Bhattacharya S, et al. Inflammation and cancer stem cells. Cancer Lett. 2014;345(2):271–278.
   PubMed Web of Science ®Google Scholar
• Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014;89(4):504–519.
   PubMed Web of Science ®Google Scholar
• Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375–384.
   PubMed Web of Science ®Google Scholar
• Choucair K, Morand S, Stanbery L, et al. A promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841–853.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Hosp Pharm. 2013;50(5):356–366.
   Google Scholar
• Rossi G, Russo A, Tagliamento M, et al. Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient. Cancers. 2020;12(5):1125.
   PubMed Web of Science ®Google Scholar
• Hashemi S, Fransen MF, Niemeijer A, et al. Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer. 2021;153:81–89.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigenspecific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 2016;22(4):433–438.
   PubMed Web of Science ®Google Scholar
• Tokumaru S, Koizumi T, Sekino Y, et al. Lymphocyte-to-Monocyte ratio is a predictive biomarker of response to treatment with Nivolumab for gastric cancer. Oncology. 2021;99(10):632–640.
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.
   PubMedGoogle Scholar
• Li J, Cheng Y, Ji Z. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: a PRISMA-compliant meta-analysis. Medicine 2019;98(2):e14091.
   PubMed Web of Science ®Google Scholar
• Gerratana L, Basile D, Toffoletto B, et al. Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Sci Rep. 2020;10(1):7010.
   PubMed Web of Science ®Google Scholar
• Gawinski C, Michalski W, Mróz A, et al. Correlation between lymphocyte-to monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and tumor-ınfiltrating lymphocytes (TILs) in left-sided colorectal cancer patients. Biology. 2022;11(3):385.
   PubMedGoogle Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl. Bratisl Lek Listy. 2001;102(1):5–14.
   PubMedGoogle Scholar
• Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–1212.
   PubMed Web of Science ®Google Scholar
• Jomrich G, Hollenstein M, John M, et al. The modified Glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. Oncotarget. 2018;9(6):6968–6976.
   PubMedGoogle Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391.
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–1690.
   PubMed Web of Science ®Google Scholar
• Shand FW, Ueha S, Otsuji M, et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc Natl Acad Sci USA. 2014;111(21):7771–7776.
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Muss HB, Shachar SS, et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971–978.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21(24):5453–5459.
   PubMed Web of Science ®Google Scholar
• Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–959.
   PubMed Web of Science ®Google Scholar
• Couchoud C, Fagnoni P, Aubin F, et al. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunol Immunother. 2020;69(10):1947–1958.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108(12):2470–2477.
   PubMed Web of Science ®Google Scholar
• Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013;49(10):2356–2364.
   PubMed Web of Science ®Google Scholar
• Hermes A, Gatzemeier U, Waschki B, et al. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer e a retrospective single institution analysis. Respir. Med. 2010;104(12):1937–1942.
   PubMed Web of Science ®Google Scholar
• Pucino V, Bombardieri M, Pitzalis C, et al. Lactate at the crossroads of metabolism, inflammation, and autoimmunity. Eur J Immunol. 2017;47(1):14–21.
   PubMed Web of Science ®Google Scholar
• Van Wilpe S, Koornstra R, Den Brok M, et al. Lactate dehydrogenase: a marker of diminished antitumor. Oncoimmunology. 2020;9(1):1731942.
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to Tcell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–745.
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114(3):256–261.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Brighenti M, Buti S, et al. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Med Oncol. 2018;35(10):132.
   PubMed Web of Science ®Google Scholar
• Yang F, Markovic SN, Molina JR, et al. Association of sex, age, and Eastern cooperative oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(8):e2012534.
   PubMed Web of Science ®Google Scholar
• Wells L, Cerniglia M, Hall S, et al. Treatment of metastatic disease with immune checkpoint inhibitors Nivolumab and pembrolizumab: effect of performance status on clinical outcomes. J Immunother Precis Oncol. 2022;5(2):37–42.
   PubMedGoogle Scholar
• Dall’Olio FG, Maggio I, Massucci M, et al. ECOG performance status 2 as a prognostic factor in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors–a systematic review and meta-analysis of real-world data. Lung Cancer. 2020;145:95–104.
   PubMed Web of Science ®Google Scholar
• Ding H, Xin W, Tong Y, et al. Cost-effectiveness of immune checkpoint inhibitors for treatment of non–small cell lung cancer: a systematic review. PLoS One. 2020;15(9):e0238536.
   PubMed Web of Science ®Google Scholar